Silicon Laboratories Inc. | ||||
Condensed Consolidated Statements of Cash Flows | ||||
(In thousands) | ||||
(Unaudited) | ||||
| ||||
| Nine Months Ended | |||
| September 29,
|
| September 30,
| |
Operating Activities |
|
|
| |
Net income | $ 68,446 |
| $ 51,944 | |
Adjustments to reconcile net income to cash provided by operating activities: |
|
|
| |
Depreciation of property and equipment | 11,781 |
| 11,068 | |
Amortization of other intangible assets and other assets | 33,322 |
| 20,531 | |
Amortization of debt discount and debt issuance costs | 9,578 |
| 6,984 | |
Stock-based compensation expense | 36,893 |
| 33,007 | |
Deferred income taxes | (2,994) |
| (5,703) | |
Changes in operating assets and liabilities: |
|
|
| |
Accounts receivable | 2,518 |
| (1,587) | |
Inventories | 5,066 |
| (13,196) | |
Prepaid expenses and other assets | 6,349 |
| 23,506 | |
Accounts payable | 8,675 |
| 1,746 | |
Other current liabilities and income taxes | (23,814) |
| 9,296 | |
Deferred income, deferred revenue and returns liability | (2,816) |
| 11,039 | |
Other non-current liabilities | (7,878) |
| (7,269) | |
Net cash provided by operating activities | 145,126 |
| 141,366 | |
|
|
|
| |
Investing Activities |
|
|
| |
Purchases of available-for-sale investments | (253,973) |
| (471,938) | |
Sales and maturities of available-for-sale investments | 371,885 |
| 143,765 | |
Purchases of property and equipment | (18,267) |
| (10,494) | |
Purchases of other assets | (9,088) |
| (2,622) | |
Acquisition of business, net of cash acquired | (239,729) |
| (13,658) | |
Net cash used in investing activities | (149,172) |
| (354,947) | |
|
|
|
| |
Financing Activities |
|
|
| |
Proceeds from issuance of long-term debt, net | -- |
| 389,468 | |
Payments on debt | -- |
| (72,500) | |
Repurchases of common stock | (24,272) |
| -- | |
Payment of taxes withheld for vested stock awards | (18,927) |
| (14,870) | |
Proceeds from the issuance of common stock | 6,585 |
| 6,836 | |
Payment of acquisition-related contingent consideration | (3,380) |
| -- | |
Net cash provided by (used in) financing activities | (39,994) |
| 308,934 | |
|
|
|
| |
Increase (decrease) in cash and cash equivalents | (44,040) |
| 95,353 | |
Cash and cash equivalents at beginning of period | 269,366 |
| 141,106 | |
Cash and cash equivalents at end of period | $225,326 |
| $236,459 |